Valeant Will Release Third-Quarter 2017 Financial Results On November 7
LAVAL, Quebec, Oct. 3, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") will release its third-quarter 2017 financial results on Tuesday, Nov. 7, 2017. Valeant will host a conference call and live web cast at 8:00 a.m. EST to discuss the results and provide a business update. All materials will be made available on the investor relations section of the Valeant web site prior to the start of the call.
Conference Call Details
|
Date: |
Tuesday, Nov. 7, 2017 |
|
Time: |
8:00 a.m. EST |
|
Webcast: |
|
|
Participant Event Dial-in: |
(844) 428-3520 (North America) |
|
(409) 767-8386 (International) | |
|
Participant Passcode: |
91700211 |
|
Replay Dial-in: |
(855) 859-2056 (North America) |
|
(404) 537-3406 (International) | |
|
Replay Passcode: |
91700211 (replay available until Jan. 7, 2018) |
About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
|
Investor Contact: |
Media Contact: |
|
Arthur Shannon |
Lainie Keller |
|
(514) 856-3855 |
(908) 927-0617 |
|
(877) 281-6642 (toll free) |

View original content with multimedia:http://www.prnewswire.com/news-releases/valeant-will-release-third-quarter-2017-financial-results-on-november-7-300528475.html
SOURCE Valeant Pharmaceuticals International, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
- Optimum Communications gets NYSE non-compliance notice over stock price
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share